Zoetis Inc. (NYSE:ZTS) Shares Sold by Fulton Bank N.A.

Fulton Bank N.A. decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.8% during the 1st quarter, Holdings Channel.com reports. The fund owned 13,893 shares of the company’s stock after selling 113 shares during the period. Fulton Bank N.A.’s holdings in Zoetis were worth $2,351,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Hohimer Wealth Management LLC lifted its stake in shares of Zoetis by 1.2% in the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock valued at $866,000 after purchasing an additional 52 shares during the period. Forum Financial Management LP increased its holdings in Zoetis by 0.8% during the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after purchasing an additional 56 shares in the last quarter. Angeles Wealth Management LLC increased its holdings in Zoetis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after purchasing an additional 56 shares in the last quarter. Prossimo Advisors LLC increased its holdings in Zoetis by 1.7% during the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after purchasing an additional 57 shares in the last quarter. Finally, River Street Advisors LLC grew its holdings in shares of Zoetis by 3.4% in the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock valued at $347,000 after acquiring an additional 58 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ZTS. Piper Sandler restated an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Stifel Nicolaus reduced their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. HSBC cut their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Barclays cut their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. Finally, The Goldman Sachs Group cut their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $211.75.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Price Performance

Shares of NYSE ZTS traded down $1.46 during midday trading on Thursday, reaching $168.20. The company’s stock had a trading volume of 3,233,673 shares, compared to its average volume of 2,955,915. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The business’s 50 day moving average price is $166.14 and its two-hundred day moving average price is $179.28. The company has a market cap of $76.75 billion, a P/E ratio of 32.41, a P/E/G ratio of 2.64 and a beta of 0.88.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same period in the previous year, the business earned $1.31 earnings per share. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. On average, analysts forecast that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.03%. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.